All Stories

  1. Reviewer recommendations and editorial outcomes in peer review: a longitudinal analysis of agreement and disagreement across review rounds
  2. Changing Your Perspective on Fatal Outcomes in Clozapine-treated patients.
  3. Psychiatry Between Ethics and Activism: Rethinking Professional Authority and Scientific Integrity in Contemporary Mental Healthcare
  4. Autonomy Under Uncertainty: Are We Overestimating Decision-Making Capacity in Psychiatric End-of-Life Contexts?
  5. Beyond Consensus, Beyond Closure: Rethinking Relapse in Schizophrenia Through a Multidimensional Lens
  6. Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia
  7. Digital Adverse Events: Rethinking Psychopathology and Public Mental Health in the Era of Human–AI Interaction
  8. Reclaiming Pharmacovigilance: Bridging the Evidence–Practice Gap in Psychopharmacology
  9. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study
  10. A Study in VigiBase of Clozapine Fatal Outcomes in 7,874 Middle-Aged versus 4,380 Young Adults
  11. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
  12. Psychiatry is not the science of unhappiness
  13. Insomnio: enfoque clínico y terapéutico
  14. Clozapine and Suicide in VigiBase
  15. Fatal Outcomes in Use of Clozapine
  16. The Crisis of Meaning in Aging and the Expansion of Medically Unjustified Euthanasia: A Psychiatric Imperative
  17. Letter to the Editor regarding: “Towards a name change of schizophrenia: positive and negative symptoms disorder (PND)”
  18. On dosing equity, scientific responsibility, and what remains unsaid
  19. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
  20. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study (Preprint)
  21. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
  22. Perceived Stress and Clinical Insomnia in Primary Care: Associations with Lifestyle and Medication Use
  23. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
  24. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
  25. The Sleep Expectation–Reality Gap: Exploring Discrepancies Between Perceived and Ideal Sleep Duration in Primary Care Patients
  26. Reflections on the Potential and Risks of AI for Scientific Article Writing after the AI Endorsement by Some Scientific Publishers: Focusing on Scopus AI
  27. Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
  28. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  29. A case of recurrent priapism during prolonged clozapine administration
  30. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
  31. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
  32. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
  33. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients
  34. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.
  35. Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
  36. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures
  37. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
  38. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
  39. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance
  40. Will ChatGPT3 Substitute for us as Clozapine Experts?
  41. Guía internacional Para una dosificación más Segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la Proteína C Reactiva y los niveles de clozapina
  42. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
  43. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
  44. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
  45. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
  46. Escaping the Long Shadow Cast by Agranulocytosis
  47. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase
  48. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES
  49. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
  50. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries
  51. Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies
  52. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase
  53. Psychometric Properties of the WHO-5 Well-Being Index among Nurses during the COVID-19 Pandemic: A Cross-Sectional Study in Three Countries
  54. Clozapine and the risk of haematological malignancies
  55. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
  56. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic
  57. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
  58. The duty to care and nurses' well-being during a pandemic
  59. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
  60. Promoting safer clozapine dosing in the Americas
  61. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  62. The Mediating Role of Resilience in the Relationship between Perceived Stress and Mental Health
  63. Miocarditis inducida por la clozapina: estudios animales pero no clínicos
  64. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries
  65. Clinimetric Criteria for Patient-Reported Outcome Measures
  66. Exploring patterns in psychiatric outpatients’ preferences for involvement in decision-making: a latent class analysis approach
  67. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
  68. An update on the complex relationship between clozapine and pneumonia
  69. Effects of a peer co-facilitated educational programme for parents of children with ADHD: a feasibility randomised controlled trial protocol
  70. Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
  71. Patient-reported well-being: psychometric properties of the world health organization well-being index in specialised community mental health settings
  72. Assessment of shared decision-making in community mental health care: Validation of the CollaboRATE
  73. Psychometric properties of the Five‐item World Health Organization Well‐being Index used in mental health services: Protocol for a systematic review
  74. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase
  75. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
  76. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics
  77. The necessity‐concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample
  78. Data From the World Health Organization’s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions
  79. Development and validation of the Patient’s Health Belief Questionnaire on Psychiatric Treatment
  80. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial
  81. Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications
  82. A Clinimetric Approach for Improving the Measurement of Pharmacophobia with Replication in Two Other Samples
  83. Meet Our Editorial Board Member
  84. Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients
  85. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela
  86. The Art of Pharmacotherapy
  87. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach
  88. Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
  89. Are Acceptance and Skepticism Determinant Factors for Adherence to Drug Treatment in Psychiatric Patients?
  90. Validity of the Control Preferences Scale in patients with emotional disorders
  91. Perceived Health Control
  92. Treatment-related decisional conflict in patients with depressive and anxious disorders
  93. The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres
  94. Preferencias por las decisiones compartidas en pacientes con depresión
  95. Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clínica
  96. Validation of the General Self-Efficacy Scale in psychiatric outpatient care
  97. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence
  98. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting
  99. What Do Psychiatric Patients Believe Regarding Where Control Over Their Illness Lies?
  100. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression
  101. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?
  102. Psychological reactance in psychiatric patients: Examining the dimensionality and correlates of the Hong Psychological Reactance Scale in a large clinical sample
  103. Psychiatric patients’ preferences and experiences in clinical decision-making: Examining concordance and correlates of patients’ preferences
  104. Validation of the Spanish version of the 9-item Shared Decision-Making Questionnaire
  105. Preferences for participation in shared decision making of psychiatric outpatients with affective disorders
  106. To what extent psychiatric patients feel involved in decision making about their mental health care? Relationships with socio-demographic, clinical, and psychological variables
  107. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
  108. Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9)
  109. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies
  110. Psychiatric outpatients' self-reported adherence versus psychiatrists' impressions on adherence in affective disorders
  111. Estrategias de manejo de los antidepresivos desde la perspectiva de los pacientes: luchando interna y externamente
  112. Attitudes toward concordance in psychiatry: a comparative, cross-sectional study of psychiatric patients and mental health professionals
  113. Psychiatric patients’ attitudes towards concordance and shared decision making
  114. Mental health professionals' attitudes to partnership in medicine taking: a validation study of the Leeds Attitude to Concordance Scale II
  115. ¿Están relacionadas la obesidad y otras comorbilidades físicas con la enfermedad mental?
  116. Editorial [Hot Topic: Compliance, Adherence and Concordance in Medicine Taking of Psychiatric Patients (Guest Editor: Carlos De las Cuevas)]
  117. Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
  118. Adaptation and validation study of the Beliefs about Medicines Questionnaire in psychiatric outpatients in a community mental health setting
  119. Antidepressant Use in Early Pregnancy
  120. Lithium Use During Early, Late Pregnancy, and Breastfeeding
  121. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment
  122. Versión española consensuada de la Severity of Dependence Scale (SDS)
  123. Fitness to Drive of Psychiatric Patients
  124. Attitudes toward psychiatric drug treatment: the experience of being treated
  125. Duloxetine-Induced Excessive Disturbing and Disabling Yawning
  126. Are psychotropics drugs used in pregnancy?
  127. Randomized Clinical Trial of Telepsychiatry through Videoconference versus Face-to-Face Conventional Psychiatric Treatment
  128. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
  129. Polypsychopharmacy
  130. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
  131. Telepsychiatry: Psychiatric consultation through videoconference patients' perception and satisfaction
  132. Telepsychiatry: Psychiatric consultation through videoconference clinical results
  133. Polypharmacy in psychiatric practice in the Canary Islands
  134. Do therapeutic indications of antidepressants change from one year to another?
  135. Telepsychiatry in the Canary Islands: user acceptance and satisfaction
  136. Telepsiquiatría: utopía o realidad asistencial
  137. Benzodiazepines: more "behavioural" addiction than dependence
  138. Burnout en los profesionales de la atención a las drogodependencias
  139. Telepsiquiatría: utopía o realidad asistencial
  140. Variations in antidepressant prescribing practice: clinical need or market influences?
  141. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study
  142. Benzodiazepine prescription is different in the public and private sectors
  143. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care
  144. Benzodiazepine audit in primary care
  145. PSYCHOPATHOLOGICAL PROFILE IN ANXIETY DISORDERS
  146. INSOMNIA AND AFFECTIVE DISORDERS